Earl Morris

Has grant

Research Assistant Professor

University of Florida
Country flagUnited States

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Earl Morris is a Research Assistant Professor at the University of Florida, USA. His research primarily focuses on medication use patterns, prescribing cascades, and the evaluation of clinical guidelines, particularly in older adults with complex health issues. Recent publications include studies on diuretic usage and hormonal contraceptives, among other topics pertinent to geriatric pharmacotherapy and medication management. He also explores the impacts of teaching methods on faculty job satisfaction in the context of skills laboratory instruction.

Recent Grants

Grant: Close

Real-World Trajectories of Xanthine Oxidase Inhibitor Use and Downstream Cardiovascular Outcomes

Open Date: 2023-01-01

Close Date: 2023-08-17

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Background Potentially inappropriate medications (PIMs) in older adults are medications in which risks often outweigh benefits and are suggested to be avoided. Worldwide, many distinct guidelines and tools classify PIMs in older adults. Collating these guidelines and tools, mapping them to a medication classification system, and creating a crosswalk will enhance the utility of PIM guidance for research and clinical practice. Methods We used the Anatomical Therapeutic Chemical (ATC) Classification System, a hierarchical classification system, to map PIMs from eight distinct guidelines and tools (2019 Beers Criteria, Screening Tool for Older Person's Appropriate Prescriptions [STOPP], STOPP‐Japan, German PRISCUS, European Union‐7 Potentially Inappropriate Medication [PIM] list, Centers for Medicare & Medicaid Services [CMS] High‐Risk Medication, Anticholinergic Burden Scale, and Drug Burden Index). Each PIM was mapped to ATC Level 5 (drug) and to ATC Level 4 (drug class). We then used the crosswalk (1) to compare PIMs and PIM drug classes across guidelines and tools to determine the number of PIMs that were index (drug‐induced adverse event) or marker (treatment of drug‐induced adverse event) drug of prescribing cascades, and (2) estimate the prevalence of PIM use in older adults continuously enrolled with fee‐for‐service Medicare in 2018 as use cases. Data visualization and descriptive statistics were used to assess guidelines and tools for both use cases. Results Out of 480 unique PIMs identified, only three medications—amitriptyline, clomipramine, and imipramine and two drug classes—N06AA (tricyclic antidepressants) and N06AB (selective serotonin reuptake inhibitors), were noted in all eight guidelines and tools. Using the crosswalk, 50% of classes of index drugs and 47% of classes of marker drugs of known prescribing cascades were PIMs. Additionally, 88% of Medicare beneficiaries were dispensed ≥1 PIM across the eight guidelines and tools. Conclusion We created a crosswalk of eight PIM guidelines and tools to the ATC classification system and created two use cases. Our findings could be used to expand the ease of PIM identification and harmonization for research and clinical practice purposes.

Year:

2023

Year:

2023

Collaborators (7)

Scott Martin Vouri

-

UNITED STATES
View details

Adam Spira

Professor

Johns Hopkins University Bloomberg School of Public Health

UNITED STATES
View details

Jennifer Albrecht

University of Maryland School of Medicine

UNITED STATES
View details

W. James Deardorff

-

UNITED STATES
View details

Shailina Keshwani

Research Assistant Professor

University of Florida

UNITED STATES
View details

Leah J Blank

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Atul Malhotra

-

UNITED STATES
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.